PMA COST-EFFECTIVENESS STUDIES SHOULD INCLUDE DATA ON SERVICES -- APhA's SCHLEGEL
Executive Summary
PMA's studies on the cost-effectiveness of drugs could be strengthened by the development of data on the cost-effectiveness of pharmaceutical services provided by pharmacists, APhA President John Schlegel, PharmD, declared during a panel discussion by pharmacy leaders at PMA's annual meeting, April 16 in Boca Raton, Florida. Commenting on the topic of new competition and opportunity in the pharmaceutical industry, Schlegel said that he "applauded" PMA's efforts to establish the cost-effectiveness of drugs through a series of studies published last year. But, Schlegel said, "it doesn't go far enough. We are looking at an issue that in my judgement is a total therapeutic benefit. We must go back together and redo those studies, and re-articulate the value of those studies in terms of the cost effectiveness of pharmaceutical products and services." In his remarks, Schlegel emphasized the theme that the drug industry and the pharmacy profession are both involved in "the much bigger business of providing therapeutic benefits." The APhA president declared: "Your products and our services are necessary together. Your products and our services alone are not sufficient to deliver to the American people what they want, what they expect, and what they have come to trust -- therapeutic benefit." Maintaining that "the 7% of the health dollar spent on pharmaceutical products and services is the best investment in health that an individual or a payor can make," Schlegel declared: "We should be creating a bigger pie and not arguing about who gets the bigger piece. The therapeutic benefits that come from the reasonably priced, high-quality products and professional services we provide are the most cost-effective and quality-of-life enhancing alternatives in the health care armamentarium. We must communicate that better in public policy forums." Schlegel told PMA that industry "must recognize that states will increasingly look to generic substitution for cost savings, and quite naturally, our pharmacists' professional skills will lead them to even greater product selection roles," Schlegel asserted. He urged: "It is most important that you decide how to approach changes in state laws with the greatest sensitivity to pharmacy. A quick decision to bring out the big guns to fight the legitimate concerns of pharmacists will quickly destroy the trust we are striving to establish."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth